Myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematologic diseases in the World Health Organization Classification characterized by clonal myeloid proliferation. The last decade has provided an immense amount of knowledge that has improved our ability to diagnose, risk stratify, and treat these blood cancers. In particular, the development of tyrosine kinase inhibitors has dramatically improved the survival in chronic myelogenous leukemia while the discovery of JAK2, MPL, CSF3R, CKIT, and CALR mutations has refined our ability to diagnose and categorize other myeloproliferative neoplasms with hope for future targeted therapies.